Story

Summit Therapeutics Rises After Bernstein Upgrade Cites More Balanced Valuation

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Summit Therapeutics Rises After Bernstein Upgrade Cites More Balanced Valuation
Text size
Background

Summit Therapeutics (SMMT) shares rose in pre-market trading after analysts at Bernstein SocGen Group upgraded the stock to Market Perform from a previous Underperform rating. The firm cited the stock's recent price decline as the primary reason for the change, arguing the valuation now more accurately reflects the risks associated with its sole late-stage drug candidate.

Analyst Recalibrates Outlook

Bernstein raised its price target on Summit Therapeutics to $11.90 from $9.80 per share. According to the firm's note, the upgrade reflects a belief that the current share price better incorporates the "risk-adjusted intrinsic value" of ivonescimab, an investigational cancer treatment.

The revision is a nuanced adjustment rather than a bullish call. Bernstein analysts stated that ivonescimab is unlikely to become a widespread replacement for Merck's blockbuster drug Keytruda across numerous cancer types. The firm noted its new price target remains below the stock's recent trading levels.

Valuation and Clinical Hurdles

As part of its revised model, Bernstein assigned a 35% probability of technical success for the pivotal ILLUMINE Phase 3 trial for ivonescimab. The analysis also factored in some potential value from other trials in indications like urothelial and head and neck cancers, though the firm views positive outcomes in those areas as unlikely.

Sample IUX Markets – In-articleAd

The upgrade comes as Summit's stock has been under significant pressure, trading near its 52-week low of $12.07 and approximately 57% below its 52-week high of $30.05. Bernstein suggested the upgrade removed a "meaningful overhang" for investors, providing a sentiment floor for the stock.

Market Context and Future Catalysts

Investors are closely watching for updates on Summit's biologics license application (BLA) for ivonescimab, which is under review by the U.S. Food and Drug Administration (FDA). The agency has set a target action date for November 2026.

While the analyst upgrade provided an immediate catalyst, Bernstein also highlighted the intense competitive pressure in the immuno-oncology market as a long-term structural concern for Summit's commercial positioning. The stock's move higher was also supported by a broadly positive session for the wider market, which provided a favorable backdrop for clinical-stage biotechnology assets.

Read next

More on Stocks
Back to latest news

LATEST